Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Brendan Teehan Biography and Net Worth

COO of ACADIA Pharmaceuticals

Brendan Teehan joined Acadia in July 2018 and has more than 25 years of global experience in the healthcare industry. He has held roles of increasing responsibility at biopharmaceutical companies, including Johnson & Johnson and Amgen, and over the course of his career he has led field sales, operations and marketing teams in the U.S. and Europe and successfully launched small and large molecule products. Mr. Teehan began his career with Johnson & Johnson, where he held a variety of commercial roles across numerous therapeutic categories including oncology, immunology, inflammation, transplantation, chronic obstructive pulmonary disease and asthma. Mr. Teehan joined Acadia from TESARO, Inc., where he served as vice president, building and leading the company’s first provider support function designed to help oncologists optimize patient care.

Mr. Teehan received his MBA from Carnegie Mellon University, Tepper School of Business and his Bachelor of Arts degree in Government and International Relations from the University of Notre Dame.

What is Brendan Teehan's net worth?: The estimated net worth of Brendan Teehan is at least $1.05 million as of November 19th, 2024. Mr. Teehan owns 62,105 shares of ACADIA Pharmaceuticals stock worth more than $1,047,711 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Teehan may own. Additionally, Mr. Teehan receives a salary of $724,310.00 as COO at ACADIA Pharmaceuticals. Learn More about Brendan Teehan's net worth.
How old is Brendan Teehan?: Mr. Teehan is currently 55 years old. There are 5 older executives and no younger executives at ACADIA Pharmaceuticals. The oldest executive at ACADIA Pharmaceuticals is Mr. Stephen R. Davis J.D., President, CEO & Director, who is 63 years old. Learn More on Brendan Teehan's age.
What is Brendan Teehan's salary?: As the COO of ACADIA Pharmaceuticals Inc., Mr. Teehan earns $724,310.00 per year. The highest earning executive at ACADIA Pharmaceuticals is Mr. Stephen R. Davis J.D., President, CEO & Director, who commands a salary of $1,460,000.00 per year. Learn More on Brendan Teehan's salary.
How do I contact Brendan Teehan?: The corporate mailing address for Mr. Teehan and other ACADIA Pharmaceuticals executives is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. ACADIA Pharmaceuticals can also be reached via phone at (858) 558-2871 and via email at [email protected]. Learn More on Brendan Teehan's contact information.
Has Brendan Teehan been buying or selling shares of ACADIA Pharmaceuticals?: Within the last three months, Brendan Teehan has sold $173,630.49 in ACADIA Pharmaceuticals stock. Most recently, Brendan Teehan sold 10,329 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a transaction totalling $173,630.49. Following the completion of the sale, the chief operating officer now directly owns 62,105 shares of the company's stock, valued at $1,043,985.05. Learn More on Brendan Teehan's trading history.
Who are ACADIA Pharmaceuticals' active insiders?: ACADIA Pharmaceuticals' insider roster includes Laura Brege (Director), Stephen Davis (CEO), James Kihara (Insider), Austin Kim (EVP), Elena Ridloff (CFO), Mark Schneyer (CFO), Srdjan Stankovic (President), and Brendan Teehan (COO). Learn More on ACADIA Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ACADIA Pharmaceuticals?: During the last year, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 170,819 shares worth more than $2,985,492.93. The most recent insider tranaction occured on November, 19th when COO Brendan Teehan sold 10,329 shares worth more than $173,630.49. Insiders at ACADIA Pharmaceuticals own 28.3% of the company. Learn More about insider trades at ACADIA Pharmaceuticals.
Information on this page was last updated on 11/19/2024.

Brendan Teehan Insider Trading History at ACADIA Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2024	Sell	10,329	$16.81	$173,630.49	62,105
8/19/2024	Sell	9,534	$15.28	$145,679.52	52,177
5/2/2024	Sell	3,477	$16.94	$58,900.38	42,133
4/8/2024	Sell	2,568	$17.87	$45,890.16	38,796
3/27/2024	Sell	5,140	$17.90	$92,006.00	36,340
2/26/2024	Sell	624	$24.67	$15,394.08	31,432
1/8/2024	Sell	731	$29.96	$21,900.76	30,949
11/20/2023	Sell	4,960	$22.64	$112,294.40	30,393
5/17/2023	Sell	14,869	$22.50	$334,552.50	24,356
5/1/2023	Sell	548	$21.18	$11,606.64	9,487
4/6/2023	Sell	1,751	$18.16	$31,798.16	8,468
2/24/2023	Sell	461	$18.78	$8,657.58	5,195
1/9/2023	Sell	532	$17.13	$9,113.16	4,549
5/2/2022	Sell	552	$18.18	$10,035.36	3,437
2/23/2022	Sell	472	$23.80	$11,233.60

Brendan Teehan Buying and Selling Activity at ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $16.87

$16.49

$17.21

50 Day Range

MA: $16.24

$14.29

$18.76

2 Week Range

Now: $16.87

$14.15

$32.59

Volume

4,937,927 shs

Average Volume

1,682,364 shs

Market Capitalization

$2.81 billion

P/E Ratio

21.63

Dividend Yield

N/A

Beta

0.4

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Brendan Teehan Biography and Net Worth

What is Brendan Teehan's net worth?

How old is Brendan Teehan?

What is Brendan Teehan's salary?

How do I contact Brendan Teehan?

Has Brendan Teehan been buying or selling shares of ACADIA Pharmaceuticals?

Who are ACADIA Pharmaceuticals' active insiders?

Are insiders buying or selling shares of ACADIA Pharmaceuticals?